Astonea Labs Ltd Stock Price Today (NSE: ASTONEALAB)
Fundamental Score
Astonea Labs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Astonea Labs Ltd share price today is ₹273.75, up +0.00% on NSE/BSE as of 3 August 2026. Astonea Labs Ltd (ASTONEALAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹297.46 (Cr). The 52-week high for ASTONEALAB share price is ₹301.30 and the 52-week low is ₹118.00. At a P/E ratio of 65.81x, ASTONEALAB is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 11.97% and a debt-to-equity ratio of 0.75.
Astonea Labs Ltd Share Price Chart — NSE/BSE Historical Performance
Astonea Labs Ltd share price chart: 5.29% return over the past month. 52-week high ₹301.30, 52-week low ₹118.00.
Astonea Labs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹273.75 | ₹273.75 | ₹273.75 | ₹273.75 | 1.00K (Cr) | |
| ₹273.75 | ₹273.75 | ₹273.75 | ₹273.75 | 0.00 (Cr) | |
| ₹273.75 | ₹273.75 | ₹273.75 | ₹273.75 | 1.00K (Cr) | |
| ₹271.00 | ₹271.00 | ₹271.00 | ₹271.00 | 0.00 (Cr) | |
| ₹264.75 | ₹271.00 | ₹264.75 | ₹271.00 | 2.00K (Cr) | |
| ₹266.00 | ₹266.05 | ₹266.00 | ₹266.05 | 2.00K (Cr) | |
| ₹261.75 | ₹261.75 | ₹261.75 | ₹261.75 | 1.00K (Cr) | |
| ₹272.45 | ₹272.45 | ₹272.45 | ₹272.45 | 1.00K (Cr) | |
| ₹278.00 | ₹278.00 | ₹278.00 | ₹278.00 | 0.00 (Cr) | |
| ₹285.80 | ₹285.80 | ₹278.00 | ₹278.00 | 2.00K (Cr) |
Astonea Labs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹273.75 | ₹273.75 | ₹273.75 | ₹273.75 | +0.00% | |
| ₹260.00 | ₹288.20 | ₹256.00 | ₹273.75 | +5.29% | |
| ₹232.00 | ₹301.30 | ₹230.55 | ₹260.00 | +12.07% | |
| ₹160.00 | ₹235.95 | ₹130.05 | ₹230.55 | +44.09% | |
| ₹150.00 | ₹165.00 | ₹150.00 | ₹160.05 | +6.70% | |
| ₹158.50 | ₹159.50 | ₹145.00 | ₹153.10 | -3.41% | |
| ₹152.50 | ₹160.00 | ₹151.50 | ₹158.50 | +3.93% | |
| ₹154.00 | ₹160.00 | ₹150.00 | ₹156.00 | +1.30% | |
| ₹150.20 | ₹163.95 | ₹137.00 | ₹163.50 | +8.85% | |
| ₹150.00 | ₹161.95 | ₹118.00 | ₹150.00 | +0.00% | |
| ₹164.90 | ₹165.00 | ₹138.05 | ₹150.00 | -9.04% | |
| ₹173.55 | ₹180.00 | ₹161.00 | ₹161.00 | -7.23% |
AI Research Briefing
Powered by Gemini · 2026-08-01
Topline growth is exploding while net profit and cash conversion are collapsing under the weight of weak internal controls.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Astonea Labs filed its FY26 Annual Report on July 24, 2026, setting its 9th AGM for August 21, 2026, to vote on Memorandum of Association alterations and subsidiary investments up to ₹100 crore. Standalone FY26 figures show revenue up 51.3% to ₹147.58 crore, but net profit dropped 15.6% to ₹4.52 crore. Statutory auditors flagged internal financial controls over financial reporting as operating ineffectively as of March 31, 2026. Earlier in July, the company monetized non-core assets, selling a Gurugram property for ₹2.99 crore, and secured a Yemen SBDMA facility inspection certificate.
CORE STORY (THE REAL GAME)
Micro-cap speculative pharma expansion vehicle riding a high-multiple re-rating cycle on cosmetic and generic manufacturing, masking thin profitability and structural control flags.
- FY26 standalone revenue rose 51.3% to ₹147.58 crore but net profit fell 15.6% to ₹4.52 crore
- Auditor flagged ineffective internal financial controls as of March 31, 2026
- Upcoming AGM on August 21, 2026 seeks sweeping MOA alterations and subsidiary expansion authority
- Successful operational turnaround of Damaira Pharmaceuticals acquisition
- Concrete revenue delivery from newly incorporated international subsidiaries
- Remediation of internal control audit qualifications
- Auditor-certified ineffective internal financial controls over financial reporting
- Abyssal 5-year cumulative free cash flow of ₹-47.4 Cr
- Extreme micro-cap liquidity trap risk with zero institutional backing (FII at 0.0%)
FII holdings dropped by 2.51% to flat 0.0%, leaving the micro-cap entirely at the mercy of retail and promoter blocks.
India pharma sector targets high-value complex generics and biopharma, but micro-cap compliance standards face severe regulatory scrutiny.
Acquired 25.74% stake in Damaira Pharmaceuticals for ₹6.25 crore; sold Gurugram property for ₹2.99 crore.
no — 5Y FCF is ₹-47.4 Cr, profits fail to materialize as cash
Consolidation near resistance with elevated downside risk if micro-cap speculative liquidity evaporates.
Primary Thesis Risk
Auditor-flagged ineffective internal controls combined with negative free cash flow make this a high-probability capital trap.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Astonea Labs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Astonea Labs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ASTONEALAB across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Balanced Promoter Holding (72.30%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 65.81x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Negative Free Cash Flow (₹-47.40 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.07%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Astonea Labs Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Astonea Labs Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Astonea Labs LtdAstonea Labs Lt...Selected✓ ASTONEALAB • 544409 | 16.8/100 | ₹273.75₹274 | ₹297.46₹297.46 | 65.81Average 65.8 Average | 11.97%Average 11.97% Average | 10.33%Average 10.33% Average | 0.75Good 0.8 Good | — — | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Astonea Labs Ltd Quarterly Performance
Latest quarterly metrics for ASTONEALAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
N/A
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Astonea Labs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ASTONEALAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Astonea Labs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Astonea Labs Ltd (ASTONEALAB) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Astonea Labs Ltd
About ASTONEALAB (Astonea Labs Ltd)
Astonea Labs Ltd is a dynamic pharmaceutical company dedicated to improving global health and well-being through the development, manufacturing, and distribution of high-quality ph...armaceutical and cosmetic products. Driven by innovation and a commitment to excellence, ASTONEALAB meticulously formulates and produces a diverse portfolio of medicines and personal care solutions designed to meet the evolving needs of patients and consumers worldwide. Our unwavering focus on research and development ensures that we remain at the forefront of scientific advancements, constantly exploring new therapeutic possibilities and pushing the boundaries of product efficacy and safety. ASTONEALAB strives to be a trusted partner for healthcare professionals and individuals seeking reliable and effective solutions for a healthier and more vibrant life. ASTONEALAB's product range encompasses a broad spectrum of therapeutic areas, addressing various health concerns and enhancing the quality of life. We offer a comprehensive selection of pharmaceutical products, including essential generic medications, over-the-counter remedies, specialized therapies targeting specific conditions, and innovative nutraceuticals designed to support overall wellness. Furthermore, ASTONEALAB's commitment to beauty and personal care is reflected in our extensive line of cosmetic products, which includes advanced skincare formulas, revitalizing haircare solutions, and age-defying treatments. Our dedication to quality extends across all product categories, ensuring that every item bearing the ASTONEALAB name meets the highest standards of purity, potency, and efficacy. ASTONEALAB operates with a global vision, extending its reach to serve diverse markets and communities around the world. We are committed to fostering strong partnerships with healthcare providers, distributors, and other stakeholders to ensure that our products are readily accessible to those who need them most. Through strategic collaborations and a robust distribution network, ASTONEALAB is expanding its presence in both established and emerging markets, bringing innovative healthcare solutions to a wider audience. We remain steadfast in our mission to make a positive impact on the health and well-being of individuals and communities worldwide, guided by our core values of integrity, innovation, and unwavering commitment to quality.
Company Details
Key Leadership
ASTONEALAB Share Price: Frequently Asked Questions
What is the current share price of Astonea Labs Ltd?
Astonea Labs Ltd (ASTONEALAB) trades at ₹273.75 on NSE and BSE. Market cap ₹297.46 (Cr). Educational data only.
What is the P/E ratio of Astonea Labs Ltd?
Astonea Labs Ltd has a P/E of 65.81x vs industry average 34.89x.
What is the Bull Run score for Astonea Labs Ltd?
Astonea Labs Ltd has a Bull Run score of 16.8/100 based on 25+ financial parameters.
Does Astonea Labs Ltd pay dividends?
Astonea Labs Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Astonea Labs Ltd?
Astonea Labs Ltd has ROE of 11.97%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Astonea Labs Ltd?
Astonea Labs Ltd has debt-to-equity of 0.75.
Is Astonea Labs Ltd a good investment?
Bull Run gives Astonea Labs Ltd a score of 16.8/100. This is not investment advice — consult a SEBI-registered advisor.